Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
While a general exclusion to weight-loss drugs is no longer permitted, a lower court will now decide whether health insurance had any reasonable justification for denying coverage in this case
In September 2025, the court issued a split ruling: it upheld FDAs determination that retatrutide did not qualify as a protein under the agencys technical definition, but it rejected FDAs reasoning for refusing to consider retatrutide an analogous product
To minimize rebound weight gain, work with your healthcare provider to develop a comprehensive plan
Additional research shows 21% of employers are evaluating GLP-1 coverage implementation within three years
So, if you take one of the newer GLP-1 medications like semaglutide or tirzepatide, you may be paying out of pocket for it
